ARKG240719P28000
- 2.62
- +0.19+7.82%
ARK Genomic Revolution ETF Newsroom
Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday.Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-
Nurix Therapeutics Q2 2024 GAAP EPS $(0.71) Misses $(0.63) Estimate, Sales $12.092M Miss $22.105M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.63) by 12.7 percent. This is a 57.78 percent decrease over losses
What Analysts Are Saying About Schrodinger Stock
During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance.
Recursion Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 65.52% Keybanc $16 → $12 Maintains Overweight 06/25/2024 134.48% Needham $17 → $17 Reiterates
BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets
Earnings Week Ahead: PepsiCo, Delta Air Lines, JPMorgan, Citigroup and More
The Fed's Ambivalence: What Investors Can Expect from Its Dovish Shift
While the Federal Reserve has kept interest rates unchanged, recently released economic data such as PCE, CPI, and the unemployment rate suggest that inflation is trending in the right direction, leading the market to believe that a cycle of decreasing interest rates will begin soon. However, the debate continues; it's not about "whether or not," but rather "when and how" rate cuts will occur.
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company's impressive second
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Schrodinger Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 48.83% Leerink Partners → $29 Initiates Coverage On → Outperform 05/02/2024 89.89% Citigroup $3
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum.
Will Trump's Debate Advantage Give Biotech and Healthcare Stocks a Lift?
As the dust settles on the latest presidential debate, market analysts are scrutinizing the implications of a potential shift in the political landscape.
Twist Bioscience Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 24.64% Barclays $45 → $60 Maintains Overweight 06/13/2024 35.02% TD Cowen $55 → $65 Maintains B
Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
In the last three months, 14 analysts have published ratings on Nurix Therapeutics (NASDAQ:NRIX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rece
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 23.99% RBC Capital $23 → $26 Maintains Outperform 06/18/2024 23.99% HC Wainwright & Co. $19 → $
Cathie Wood's Top and Bottom Performing ARKK Holdings of H1
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.